![Mounia Chaoui-Roulleau](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mounia Chaoui-Roulleau
Directeur/Membre du Conseil chez
Institut National de la Santé & de la Recherche Médicale
Profil
Mounia Chaoui-Roulleau currently works at Institut National de la Santé & de la Recherche Médicale, as Director, Eye Tech Care SA, as Director from 2014, PhysioAssist SAS, as Director, Turenne Capital Partenaires SA, as Partner from 2013, Intrexon ActoBiotics NV, as Member-Supervisory Board from 2014, and Themis Bioscience GmbH, as Member-Supervisory Board.
Dr. Chaoui-Roulleau also formerly worked at Finbiomed SARL, as Chief Executive Officer from 2013 to 2020, BioVex, Inc., as Director from 2009 to 2011, Xytis, Inc., as Director, TiGenix NV, as Non-Executive Director, Kiora Pharmaceuticals, Inc., as Director from 2013 to 2016, SCYNEXIS, Inc., as Independent Director in 2014, Aptanomics SA, as Director, Prosonix Ltd., as Non-Executive Director, TiGenix SAU, as Director from 2007 to 2012, Funxional Therapeutics Ltd., as Director from 2011 to 2012, DNA Therapeutics SASU, as Director, Amolyt Pharma SAS, as Director, Millendo Therapeutics SAS, as Director, Altran Technologies SA, as Principal from 1999 to 2001, Sofimac Innovation SAS, as Managing partner from 2012 to 2020, Telesis, as Principal in 1999, Ventech SA, as General Partner from 2011 to 2013, INSERM Transfert SA, as Managing Partner in 2012, and Covagen AG, as Member-Supervisory Board.
Dr. Chaoui-Roulleau received her undergraduate degree in 1995 from École Centrale Paris and doctorate degree from Université Pierre et Marie Curie.
Postes actifs de Mounia Chaoui-Roulleau
| Sociétés | Poste | Début |
|---|---|---|
Institut National de la Santé & de la Recherche Médicale
 Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Research institute | Directeur/Membre du Conseil | 25/11/2009 |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Manufactures biopharmaceutical products | Directeur/Membre du Conseil | - |
Eye Tech Care SA
 Eye Tech Care SA Medical SpecialtiesHealth Technology Develops medical devices for non-invasive eye disease treatment | Directeur/Membre du Conseil | 01/07/2014 |
Physio-Assist SAS
 Physio-Assist SAS Medical SpecialtiesHealth Technology Develops and manufactures medical equipment | Directeur/Membre du Conseil | - |
Turenne Capital Partenaires SA
 Turenne Capital Partenaires SA Investment ManagersFinance Turenne Capital invests in small and middle market companies located in France. The firm focuses on healthcare, hospitality, environment, energetic transition and innovacom sectors. It participates in seed, early and later stage transactions with an investment size of less than EUR 30 million. | Private Equity Investor | 01/05/2013 |
Anciens postes connus de Mounia Chaoui-Roulleau
| Sociétés | Poste | Fin |
|---|---|---|
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops vaccines to prevent infectious diseases | Directeur/Membre du Conseil | 27/07/2022 |
Sofimac Innovation SAS
 Sofimac Innovation SAS Investment ManagersFinance Sofimac Innovation is an active manager which prefers to invest equity to create or grow limited liability companies in the ICT sector. The firm invests principally in France and Western European countries because they believe that geographical proximity between investee companies and their team is necessary to provide effective support. Sofimac Innovation typically invests €0.5-€1.5 million in the first round in early-stage companies and €0.5-€3 million with co-investors in subsequent rounds when necessary. The firm works in partnership with their investee companies, providing expertise to support them in assessing and positioning their new technology in their competitive environment, measuring and developing the managing team's potential for success and building the foundations that will allow the company to transform the initial concept into reality. Sofimac Innovation aims to invest in companies which have a technological innovation with growth potential, a quality management team, technological intensity and barriers to entry (including intellectual property rights ownership), a large target market with significant growth potential, a robust marketing strategy and a project in its final stage of development. | Private Equity Investor | 31/12/2020 |
Finbiomed SARL | Directeur Général | 31/12/2020 |
| KIORA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 22/06/2016 |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Mounia Chaoui-Roulleau
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
70
Relations au 1er degré
27
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 27 |
|---|---|
Altran Technologies SA
 Altran Technologies SA Packaged SoftwareTechnology Services Develops software, digital tools and technology for the physical engineering & product development sectors | Technology Services |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases | Health Technology |
Xytis, Inc.
 Xytis, Inc. BiotechnologyHealth Technology Develops & discovers CNS drug candidates | Health Technology |
TiGenix NV
 TiGenix NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on developing and commercializing novel therapeutic | Health Technology |
Kiora Pharmaceuticals, Inc.
 Kiora Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and commercializes therapies for the treatment of ophthalmic diseases | Health Technology |
Sofimac Innovation SAS
Sofimac Innovation SAS Investment ManagersFinance Sofimac Innovation is an active manager which prefers to invest equity to create or grow limited liability companies in the ICT sector. The firm invests principally in France and Western European countries because they believe that geographical proximity between investee companies and their team is necessary to provide effective support. Sofimac Innovation typically invests €0.5-€1.5 million in the first round in early-stage companies and €0.5-€3 million with co-investors in subsequent rounds when necessary. The firm works in partnership with their investee companies, providing expertise to support them in assessing and positioning their new technology in their competitive environment, measuring and developing the managing team's potential for success and building the foundations that will allow the company to transform the initial concept into reality. Sofimac Innovation aims to invest in companies which have a technological innovation with growth potential, a quality management team, technological intensity and barriers to entry (including intellectual property rights ownership), a large target market with significant growth potential, a robust marketing strategy and a project in its final stage of development. | Finance |
Telesis
 Telesis Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Commercial Services |
Turenne Capital Partenaires SA
Turenne Capital Partenaires SA Investment ManagersFinance Turenne Capital invests in small and middle market companies located in France. The firm focuses on healthcare, hospitality, environment, energetic transition and innovacom sectors. It participates in seed, early and later stage transactions with an investment size of less than EUR 30 million. | Finance |
Ventech SA
 Ventech SA Investment ManagersFinance Ventech invests in companies located in Europe, primarily in France, Germany, the DACH region, the Nordics region and the United States. The firm focuses on a broad range of sectors and industries. It participates in pre-seed, seed and early stage capital requirements with an investment size of EUR 0.15 - 5 million. | Finance |
SCYNEXIS, Inc.
 SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
Aptanomics SA
 Aptanomics SA Pharmaceuticals: MajorHealth Technology Develops and manufactures novel therapeutics | Health Technology |
INSERM Transfert SA
 INSERM Transfert SA Investment ManagersFinance ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing. ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions. | Finance |
Institut National de la Santé & de la Recherche Médicale
Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Research institute | Commercial Services |
École Centrale Paris
 École Centrale Paris Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université Pierre et Marie Curie
 Université Pierre et Marie Curie Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
Prosonix Ltd.
 Prosonix Ltd. Pharmaceuticals: MajorHealth Technology Develops a portfolio of inhaled respiratory medicines | Health Technology |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Funxional Therapeutics Ltd.
 Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Provides drug and therapeutical development services | Health Technology |
DNA Therapeutics SASU
 DNA Therapeutics SASU BiotechnologyHealth Technology Engages in the development of drugs for cancer treatment | Health Technology |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Develops medical devices for non-invasive eye disease treatment | Health Technology |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Develops next generation protein drugs for the treatment of inflammatory diseases and cancer | Health Technology |
Millendo Therapeutics SAS
 Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Provides pharmaceutical research services | Health Technology |
Themis Bioscience GmbH
Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops vaccines to prevent infectious diseases | Health Technology |
Finbiomed SARL | |
Amolyt Pharma SAS
 Amolyt Pharma SAS Miscellaneous Commercial ServicesCommercial Services Engages in research and development in physical & natural sciences | Commercial Services |
Physio-Assist SAS
Physio-Assist SAS Medical SpecialtiesHealth Technology Develops and manufactures medical equipment | Health Technology |
